The price of the shares of the pharmaceutical company Johnson & Johnson registered a fall of 2 % in the New York Stock Exchange after the regulators of the United States recommended to suspend the use of its vaccine against Covid-19.

Specifically, the laboratory’s titles stood at $ 156.86 at the opening, compared to the 161.64 registered at the end of Monday (-2.95 %).

After that initial decline, the price has softened its fall, but has remained close to a 2 % drop until the mid-session.

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) recommended this week to suspend the administration of the vaccine Janssen, from Johnson & Johnson, after having detected six possible cases of thrombi in patients inoculated with the vaccine.

The number detected, and whose cause is not yet certain, is enormously low compared to the 6.8 million injections of the vaccine that have been administered in the United States.

Following that suspension recommendation, Janssen decided to delay the launch of its Covid-19 vaccine in Europe.

K. Tovar

Source: dpa

La entrada Johnson & Johnson’s stock market value falls apareció primero en Bitfinance.